In a study of multiple models of hyperinflammation, ruxolitinib was effective in reducing inflammation including a murine model of HLH as in the preceding study, and reduced IL-6 production by macrophages in vitro (59). The gene discussed is IL6; the disease is hemophagocytic syndrome.